Disease details

Clinical trials : 3,342 / Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04626921 (ClinicalTrials.gov)	October 22, 2020	30/10/2020	A Multi-Center, Open-Label Long-Term Extension Study of CNM-Au8 In Patients With Stable Relapsing Multiple Sclerosis	VISIONARY-MS LTE: A Multi-Center, Open-Label Long-Term Extension Study Assessing the Safety, Efficacy, Tolerability, and Pharmacokinetics of CNM-Au8 In Patients With Stable Relapsing Multiple Sclerosis	Relapsing Multiple Sclerosis	Drug: CNM-Au8	Clene Nanomedicine	George Clinical	Active, not recruiting	18 Years	55 Years	All	150	Phase 2/Phase 3	Australia
2	NCT03993171 (ClinicalTrials.gov)	December 19, 2019	31/5/2019	31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Multiple Sclerosis.	A Phase 2, Open-Label, Sequential Group, Investigator Blinded Study of Magnetic Resonance Spectroscopy (31P-MRS) to Assess the Effects of CNM-Au8 for the Bioenergetic Improvement of Impaired Neuronal Redox State in Multiple Sclerosis.	Relapsing Remitting Multiple Sclerosis	Drug: gold nanocrystals	Clene Nanomedicine	University of Texas Southwestern Medical Center	Recruiting	18 Years	55 Years	All	30	Phase 2	United States
3	NCT03536559 (ClinicalTrials.gov)	November 23, 2018	2/5/2018	Nanocrystalline Gold to Treat Remyelination Failure in Chronic Optic Neuropathy In Multiple Sclerosis	A Phase 2, Randomized, DB-PC, Parallel Group Study for the Treatment of Visual Pathway Deficits In Chronic Optic Neuropathy to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of CNM-Au8 For Remyelination In Multiple Sclerosis	Relapsing Remitting Multiple Sclerosis;Optic Neuropathy;Optic; Neuritis, With Demyelination	Drug: CNM-Au8;Drug: Placebo	Clene Nanomedicine	Clene Australia Pty Ltd	Active, not recruiting	18 Years	55 Years	All	76	Phase 2	United States;Australia;Canada